Status:

COMPLETED

Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer

Lead Sponsor:

Takeshi Morimoto

Collaborating Sponsors:

Bayer Yakuhin, Ltd.

Conditions:

Venous Thrombosis

Neoplasms

Eligibility:

All Genders

20-80 years

Phase:

PHASE4

Brief Summary

The primary purpose of this study is to determine the optimal duration of anticoagulation therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for cancer-associated low-risk pulmo...

Detailed Description

Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), is a major health problem in the world. There have been many clinical studies evaluating VTE, although d...

Eligibility Criteria

Inclusion

  • Patients with active cancer (solid and hematologic malignancies) presenting with objectively newly confirmed pulmonary embolism who are scheduled to be treated by anticoagulation therapy.
  • Patients with an simplified Pulmonary Embolism Severity Index (PESI) score of 1 or less

Exclusion

  • Contraindicated patients for rivaroxaban (Clinically significant liver disease, Bacterial endocarditis, Active bleeding, Inadequate contraceptive measures if of childbearing potential, Concomitant use of strong cytochrome P-450 3A4 inhibitors or inducers or P-glycoprotein inhibitors or inducers)
  • Expected life expectancy \<6 months
  • Patients who do not provide written informed consent
  • Patients who judged to be inappropriate for enrolment by the physician (including patients at a high risk of gastrointestinal or genitourinary bleeding)

Key Trial Info

Start Date :

February 18 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2024

Estimated Enrollment :

179 Patients enrolled

Trial Details

Trial ID

NCT04724460

Start Date

February 18 2021

End Date

December 31 2024

Last Update

March 11 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Kyoto, Kyoto, Japan, 606-8507